drugset / Trial / NCT00473135

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

Dengue fever, caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a 2-dose regimen of a new monovalent dengue virus vaccine. This study will test the dengue virus vaccine DEN1delta30 in healthy adults.

Timeline

Start
2007-05
Primary completion
2010-01
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rDEN1delta30 Vaccine 1000 unknown Subcutaneous

Indications